laxis against malaria, it was observed that rheumatic symptoms in patients treated with quinine or synthetic antimalarials such as quinacrine improved. Such observations opened the door for regular treatment of patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) with quinacrine and the subsequently synthesized drugs such as chloroquine and hydroxychloroquine (HCQ). 1 The immunomodulatory effect of antimalarials is mediated by several mechanisms. Interference with antigen processing by means of rising lysosomal pH and modulation of immune response mediated by tolllike receptor 9 may be important pharmacological actions. 2, 3 Of note, although processing of lowaffinity antigens (such as self antigens) is blocked, the immune response against high-affinity antigens (such as bacterial peptides) is not impaired, which results in an effective immunomodulation without immunosuppression. 2 Because of these modulatory effects on the autoimmune response, antimalarials have been widely used to treat mild manifestations of SLE, particularly arthritis and skin rashes, for years. In 1991, an important study, the Canadian Hydroxychloroquine Study, was published. 4 In this small clinical trial, patients on stable SLE and HCQ treatment were randomized either to continue the drug or to take placebo. Over the next 24 weeks, patients on no antimalarials were significantly more likely to suffer lupus flares, including severe flaresalthough the differences in the frequency of the latter did not reach the statistical (P < 0.05) level. For the first time, HCQ was shown to be an effective drug to maintain SLE (not only minor manifestations) in remission. Two further small clinical trials were published, showing efficacy in articular and skin manifestations 5 and joint pain. 6 Finally, a randomised clinical trial performed in pregnant women showed that both SLE activity and prednisone doses were lower at the end of pregnancy among women randomised to take HCQ as compared with those taking placebo. 7 More recently, an observational study from the Hopkins Lupus Cohort has shown similar results when HCQ is withdrawn in pregnant womenthat is, an increased number of flares. 8 The same group observed an adjuvant effect of HCQ and mycophenolate mofetil in controlling membranous lupus nephritis. 9 In a nested cohort study of US military personnel who later developed SLE, those treated with HCQ at the onset of symptoms had a longer course until fulfilment of American College of Rheumatology (ACR) criteria, as well as a lower number of autoantibodies at the time of diagnosis. 10 However, effects of antimalarials go far beyond their immunomodulatory effects. They have consistently been shown to reduce cholesterol levels in cohort studies. [11] [12] [13] [14] Recently, an observational study with a follow-up longer than 20 years has shown a 38% risk reduction of developing diabetes mellitus among patients with RA after adjusting for sex, age, race, education, disease duration and treatment with prednisone. 15 This study also showed a remarkable dose effect, with the lowest incidence of diabetes among patients treated with HCQ for more than 4 years. These metabolic effects could explain in part the results of a recent study showing a protective effect of HCQ against the development of carotid plaque. 16 Indeed, data point to a broader beneficial effect of antimalarials with regard to cardiovascular disease. Intrinsic antithrombotic properties have been shown in animal models. 17, 18 In the field of clinical practice, a reduction in the frequency of thrombosis among patients treated with HCQ was first suggested by Wallace. 19 Petri et al. 20 found a similar inverse association between antimalarial use and thrombotic events. Erkan et al. 21 showed a protective effect of HCQ against thrombosis in patients with antiphospholipid antibodies, both with and without lupus. Several studies did not find an association between antimalarial treatment and less thrombosis; however, the temporal relationship between treatment and events was not taken into account. 22, 23 Recently, an observational study from Spain has found a strong and independent antithrombotic effect of antimalarials in a time-varying Cox model. 24 Risk factors for thrombosis included previous events and the presence of antiphospholipid antibodies. Only 17% of thrombotic events happened while the patients were actually taking antimalarials.
An additional beneficial effect of antimalarials has just been reported. Chloroquine has been successfully used as adjuvant therapy for glioblastoma multiforme. 25 Several potential antineoplastic effects of antimalarials have been described, including DNA-stabilizing properties and inhibition of telomerase, the 'immortality' enzyme of tumour cells. 25, 26 In patients with lupus, treatment with antimalarials has been shown to reduce the risk of cancer in an observational, single-centre cohort. 26 Although this effect should be confirmed in larger and ethnically diverse populations, the overall beneficial effect of antimalarials in SLE seems further reinforced.
Expectedly, HCQ treatment prevented the accrual of irreversible damage in patients from the LUMINA cohort. Antimalarials, thus, directly reduce the frequency of three of the main causes of death in SLE patients (disease activity flares, thrombosis and, maybe, cancer) as well as the overall burden of organ damage, which has major adverse prognostic implications. 27 The first study showing a reduction in mortality of at least 50% among patients with lupus treated with antimalarials, as compared with those never treated, was published in LUPUS in 2006. 24 Subsequently, a second independent study with similar results was released in 2007. 28 Both studies had a similar design, with a propensity score analysis of prospective observational cohorts. This statistical tool provides an adjustment that balances a large number of covariates between treated and untreated/control groups, resulting in a kind of pseudorandomisation. The results of the two studies are, thus, as solid as those coming from observational studies can be.
In this issue of LUPUS, the article by Siso et al. 29 confirms the beneficial long-term effect of antimalarial treatment in patients with SLE. This is a study that, although retrospective in design, includes a large series of 206 patients, all with biopsy-proven lupus nephritis, from a well-characterised lupus cohort. Patients treated with antimalarials had a lower frequency of hypertension, thrombosis, infection, end-stage renal failure and death. No patient treated with antimalarials died of either infection, thrombosis or cancer.
These results, thus, support previous prospective studies. Moreover, the study focuses on patients with lupus nephritis and suggests that the beneficial effects of antimalarials are not limited to patients with mild lupus. Accordingly, once HCQ has been started, it should not be stopped even if the patient suffers more serious organic lupus involvement, whether or not more aggressive immunosuppressive treatment is given.
In the current climate of evidence-based medicine, data not supported by randomised clinical trials are often labelled as dubious. However, results from the studies analysing the role of antimalarials in SLE are so congruent in the same direction that, today, placebo-controlled trials could be considered unethical. In addition, the safety profile of these compounds, particularly HCQ, is so favourable that the price to pay for its use seems very low. The logical consequence of the evidence available might be the universal use of antimalarials in all patients with SLE, starting as soon as the diagnosis has been made, and maintained for an indefinite period. This includes pregnancy, a period when antimalarials should not be discontinued due to the risk of maternal flares 8 and the safety for the foetus. 30 We conclude that, today, a very old treatment still constitutes one of the main weapons to fight SLE.
